B
Bull
Bull · 25%DMAC
$4.83
情境價格
$6.390
-0.341 (-5.33%)收盤時
Loading chart…
- High
- 6.740
- Open
- 6.720
- VWAP
- 6.49
- Vol
- 116.51K
- Mkt Cap
- 115.79M
- Low
- 6.340
- Amount
- 756.12K
- EV/EBITDA, TTM
- 0.00
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
AI analysis of DiaMedica Therapeutics Inc (DMAC)
holdCurrently, DMAC is not a strong buy due to its low RSI of 32.792, indicating oversold conditions, and a significant net loss of $10.1 million in Q2 2026. Although the stock has potential for recovery given its recent price fluctuations, the financial pressures and increasing R&D expenses pose risks.
估值指標
The current forward P/E ratio for DiaMedica Therapeutics Inc (DMAC) is 0.00, compared to its 5-year average forward P/E of -4.73.
Alphio AI Price Scenarios for DMAC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding DMAC
事件時間軸
資訊
9.508-18NASDAQ.COMDiaMedica Reports Q2 2026 Financial Results and Clinical Updates
2.008-10NewsfilterDiaMedica Completes Enrollment in Early-Onset Fetal Growth Restriction Trial
- 5.007-17Newsfilter
DiaMedica Grants Stock Options to New Employee
- 9.006-23Newsfilter
First Clinical Evaluation of DM199 for Fetal Growth Restriction
- 9.006-16Newsfilter
DiaMedica Plans Pharmacokinetic Study for Preeclampsia
DMAC FAQ — answered by Alphio AI
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, DMAC is not a strong buy due to its low RSI of 32.792, indicating oversold conditions, and a significant net loss of $10.1 million in Q2 2026. Although the stock has potential for recovery given its recent price fluctuations, the financial pressures and increasing R&D expenses pose risks.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。